Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadroparin for survival in advanced lung, pancreas, or prostate cancer
NCT00312013Phase 3Completed
- Sponsor
- GSK
- Start
- May 2006
- Primary completion
- Jul 2009
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of nadroparin in prostate cancer (PCa), Pancreatic carcinoma (PC), non-small cell lung cancer (NSCLC), sponsored by GSK. Started May 2006; status: completed.
02
Drugs
nadroparin
03
Conditions
prostate cancer (PCa)Pancreatic carcinoma (PC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00312013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00312013.